Navigation Links
Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
Date:9/5/2008

PRINCETON, N.J., Sept. 5 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) management will present at the 3rd Annual Citi Biotech Day being held September 8, 2008, at the Citi Executive Conference Center, New York, NY. Management will also present at the Morgan Stanley Global Healthcare Unplugged Conference on September 9, 2008, at the Grand Hyatt Hotel, New York, NY. Schaefer Price, Pharmasset's Chief Executive Officer, will provide a brief overview of the company followed by a question and answer session at both conferences.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.
Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Kurt Leutzinger

Chief Financial Officer

kurt.leutzinger@pharmasset.com

Office: +1 (609) 613-4110


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
2. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
3. Pharmasset Joins Russell 3000 Index
4. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
5. Pharmasset Selected to Join the NASDAQ Biotechnology Index
6. Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th
7. Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
8. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
9. Pharmasset Receives $10 Million of Working Capital
10. Pharmasset Appoints Herbert J. Conrad as a Director
11. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... 2017 Aratana Therapeutics, Inc. (NASDAQ: ... licensing, development and commercialization of innovative biopharmaceutical products for ... in North America 2016. ... based on the FDA approval of three innovative therapeutics ... (capromorelin oral solution) and NOCITA ® (bupivacaine ...
(Date:1/20/2017)... -- http://www.Financialbuzz.com - According to ... of death worldwide. There were 8.2 million cancer related ... deaths increased gradually over time, the death rates have ... cancers continues to drive demand of biological therapies for ... Insights, Inc. cancer biological therapy market size was USD 61.3 ...
(Date:1/19/2017)... 19, 2017 /PRNewswire -- WuXi AppTec, a leading ... and technology platform, today announced that it has ... preclinical drug discovery contract research organization (CRO). After ... wholly-owned subsidiary of WuXi, and will continue to ... greater services. The acquisition will further strengthen WuXi,s ...
(Date:1/19/2017)... 19, 2017  ArmaGen, Inc., today announced that ... as chief executive officer, as well as a ... to ArmaGen more than 17 years of executive ... of biotherapeutics and pharmaceuticals. "Mathias ... experience and skillset necessary to lead ArmaGen to ...
Breaking Biology Technology:
(Date:1/4/2017)... 2017  CES 2017 – Valencell , the ... announced the launch of two new versions of ... biometric sensor modules that incorporate the best of ... expertise. The two new designs include Benchmark BE2.0, ... and Benchmark BW2.0, a 2-LED version of its ...
(Date:12/20/2016)... RALEIGH, N.C. and GENEVA, Dec, 20, 2016 ... performance biometric data sensor technology, and STMicroelectronics ... across the spectrum of electronics applications, announced today ... scalable development kit for biometric wearables that includes ... integrated with Valencell,s Benchmark™ biometric sensor ...
(Date:12/15/2016)... VANCOUVER, Canada and BADEN-BADEN, Germany ... Solutions, a leading global financial services provider, today announced an ... in passive behavioural biometrics, to join forces. The partnership will ... fraud mitigation strategies in compliance with local data protection regulation. ... In ...
Breaking Biology News(10 mins):